Apogenix AG: Publication in Human Vaccines & Immunotherapeutics Illustrates the Advantages of Hexavalent CD40 Agonists in Targeting CD40 in Immuno-Oncology • MC Services corporate website
19 Sep Apogenix AG: Publication in Human Vaccines & Immunotherapeutics Illustrates the Advantages of Hexavalent CD40 Agonists in Targeting CD40 in Immuno-Oncology